Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2008-2-26
pubmed:abstractText
The objective of this study was to determine the population pharmacokinetic parameters of levofloxacin, gatifloxacin, and moxifloxacin following multiple oral doses. Twenty-nine patients with tuberculosis at the University Hospital in Vitória, Brazil, participated. Subjects received multiple doses of one drug (levofloxacin, 1,000 mg daily, or gatifloxacin or moxifloxacin, 400 mg daily) as part of a 7-day study of early bactericidal activity. Serum samples were collected over 24 h after the fifth dose and assayed using validated high-performance liquid chromatography assays. Concentration-time data were analyzed using noncompartmental, compartmental, and population methods. The three drugs were well tolerated. Levofloxacin produced the highest maximum plasma concentrations (median, 15.55 microg/ml; gatifloxacin, 4.75 microg/ml; moxifloxacin, 6.13 microg/ml), largest volume of distribution (median, 81 liters; gatifloxacin, 79 liters; moxifloxacin, 63 liters), and longest elimination half-life (median, 7.4 h; gatifloxacin, 5.0 h; moxifloxacin, 6.5 h). A one-compartment model, with or without weight as a covariate, adequately described the data. Postmodeling simulations using median population parameter estimates closely approximated the median values from the original data. Area under the concentration-time curve/MIC ratios for free drug were high. All three quinolones showed favorable pharmacokinetic and pharmacodynamic indices, with the most favorable results in this population being seen with levofloxacin at the comparative doses used.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/18070980-12381217, http://linkedlifedata.com/resource/pubmed/commentcorrection/18070980-1244564, http://linkedlifedata.com/resource/pubmed/commentcorrection/18070980-12588714, http://linkedlifedata.com/resource/pubmed/commentcorrection/18070980-14555582, http://linkedlifedata.com/resource/pubmed/commentcorrection/18070980-15024625, http://linkedlifedata.com/resource/pubmed/commentcorrection/18070980-15478070, http://linkedlifedata.com/resource/pubmed/commentcorrection/18070980-15528718, http://linkedlifedata.com/resource/pubmed/commentcorrection/18070980-16048921, http://linkedlifedata.com/resource/pubmed/commentcorrection/18070980-16584284, http://linkedlifedata.com/resource/pubmed/commentcorrection/18070980-16675781, http://linkedlifedata.com/resource/pubmed/commentcorrection/18070980-17145798, http://linkedlifedata.com/resource/pubmed/commentcorrection/18070980-17517835, http://linkedlifedata.com/resource/pubmed/commentcorrection/18070980-7878693
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0066-4804
pubmed:author
pubmed:issnType
Print
pubmed:volume
52
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
852-7
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis.
pubmed:affiliation
Infectious Disease Pharmacokinetics Laboratory, National Jewish Medical and Research Center, Denver, CO 80206, USA. peloquinc@njc.org
pubmed:publicationType
Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural